1. Home
  2. XWEL vs LEXX Comparison

XWEL vs LEXX Comparison

Compare XWEL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWEL

XWELL Inc.

HOLD

Current Price

$0.98

Market Cap

9.2M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$14.15

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XWEL
LEXX
Founded
2006
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
8.7M
IPO Year
2010
2011

Fundamental Metrics

Financial Performance
Metric
XWEL
LEXX
Price
$0.98
$14.15
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
31.3K
70.2K
Earning Date
05-19-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,210,000.00
$705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.26
$0.35
52 Week High
$2.20
$13.93

Technical Indicators

Market Signals
Indicator
XWEL
LEXX
Relative Strength Index (RSI) 45.76 69.50
Support Level $0.86 $0.62
Resistance Level $1.15 $12.89
Average True Range (ATR) 0.07 1.41
MACD 0.00 -0.06
Stochastic Oscillator 27.86 67.63

Price Performance

Historical Comparison
XWEL
LEXX

About XWEL XWELL Inc.

XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: